Please Wait.....
Report
South & Central America Glycomic Therapeutics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher's Disease, MPS-1 & IV, Cancer, Alzheimer's Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]
Market Report I 2022-11-18 I 191 Pages I The Insight Partners
The glycomic therapeutics market in South & Central America is expected to grow from US$ 8.65 billion in 2022 to US$ 20.68 billion by 2028; it is estimated to grow at a CAGR of 14.5% from 2022 to 2028.
Application in Treatment of Broad Range of Disorders Drives Market Growth
Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation. The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.
For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.
In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet, a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, is providing the funds to enhance the quality of life of Canadians.
In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions. These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.
Market Overview
The South & Central America glycomic therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. The glycomic therapeutics market in South & Central America is expected to grow due to the growing pharmaceutical industry landscape, rising healthcare expenditure, and growing education programs and conferences.
South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)
South & Central America Glycomic Therapeutics Market Segmentation
TheSouth & Central America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.
Based on class, the South & Central America glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the South & Central America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the South & Central America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher's disease, MPS-1 & IV, cancer, alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the South & Central America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the South & Central America glycomic therapeutics market is segmented into Brazil, Argentina, and the Rest of South & Central America. The Rest of South & Central America dominated the market in 2022. BioMarinPharmaceutical Inc.; GenzymeCorporation (Sanofi); BayerAG; Alzheon, Inc.; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Ltd. are the leading companies operating in the glycomic therapeutics in South & Central America.
TABLE OF CONTENTS
1. Introduction
1.1 Study Scope
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South & Central America Glycomic Therapeutics Market - By Class
1.3.2 South & Central America Glycomic Therapeutics Market - By Structures
1.3.3 South & Central America Glycomic Therapeutics Market - By Indications
1.3.4 South & Central America Glycomic Therapeutics Market - By Mode of Action
1.3.5 South & Central America Glycomic Therapeutics Market - By Country
2. South & Central America Glycomic Therapeutics Market- Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South & Central America Glycomic Therapeutics Market - Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 South & Central America - PEST Analysis
4.3 Expert Opinion
5. South & Central America Glycomic Therapeutics Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes
5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics
5.2 Market Restraints
5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.
5.3 Market Opportunities
5.3.1 Wide Applications of Glycomics in Therapeutics
5.4 Future Trends
5.4.1 New Tools in Glycomics Research
5.5 Impact Analysis
6. Glycomic Therapeutics Market- South & Central America Analysis
6.1 South & Central America Glycomic Therapeutics Market Revenue Forecast and Analysis
6.1.1 South & Central America: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)
7. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028- by Class
7.1 Overview
7.2 South & Central America Glycomic Therapeutics Market, By Class 2022 & 2028 (%)
7.2.1 South & Central America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
7.3 Isolated
7.3.1 Overview
7.3.2 South & Central America Isolated Revenue and Forecast to 2028 (US$ Million)
7.4 Synthetic
7.4.1 Overview
7.4.2 South & Central America Synthetic - Revenue and Forecast to 2028 (US$ Million)
8. South & Central America Glycomics Therapeutics Market Analysis and Forecasts To 2028 - By Indication
8.1 Overview
8.2 South & Central America Glycomics Market, By Indication 2022 & 2028 (%)
8.2.1 South & Central America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
8.3 Thrombosis and Chemoprophylaxis
8.3.1 Overview
8.3.2 South & Central America Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)
8.4 Anaemia
8.4.1 Overview
8.4.2 South & Central America Anaemia Revenue and Forecast to 2028 (US$ Million)
8.5 Anti-adhesive and Anti-inflammatory
8.5.1 Overview
8.5.2 South & Central America Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)
8.6 Cataract
8.6.1 Overview
8.6.2 South & Central America Cataract Revenue and Forecast to 2028 (US$ Million)
8.7 Gaucher's diseases
8.7.1 Overview
8.7.2 South & Central America Gaucher's diseases Revenue and Forecast to 2028 (US$ Million)
8.8 MPS-1 & IV
8.8.1 Overview
8.8.2 South & Central America MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)
8.9 Cancer
8.9.1 Overview
8.9.2 South & Central America Cancer Revenue and Forecast to 2028 (US$ Million)
8.10 Alzheimer's
8.10.1 Overview
8.10.2 South & Central America Alzheimer's Revenue and Forecast to 2028 (US$ Million)
8.11 Influenza Type A and B
8.11.1 Overview
8.11.2 South & Central America Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 South & Central America Others Revenue and Forecast to 2028 (US$ Million)
9. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Structures
9.1 Overview
9.2 South & Central America Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)
9.2.1 South & Central America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
9.2.1.1 South & Central America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
9.2.1.2 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
9.2.1.3 South & Central America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
9.2.1.4 South & Central America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
9.3 Glycoproteins
9.3.1 Overview
9.3.2 South & Central America Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Targeting Sialic Acid
9.4.1 Overview
9.4.2 South & Central America Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)
9.4.3 Zanamivir
9.4.3.1 Overview
9.4.3.2 South & Central America Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.4.4 Oseltamivir
9.4.4.1 Overview
9.4.4.2 South & Central America Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)
9.5 Proteoglycans
9.5.1 Overview
9.5.2 South & Central America Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans
9.6.1 Overview
9.6.2 South & Central America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7 Targeting Glycosaminoglycans
9.7.1 Overview
9.7.2 South & Central America Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)
9.7.3 Heparin
9.7.3.1 Overview
9.7.3.2 South & Central America Heparin - Market Revenue and Forecast to 2028 (US$ Million)
9.7.4 Hyaluronan (HA)
9.7.4.1 Overview
9.7.4.2 South & Central America Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)
9.7.5 Laronidase
9.7.5.1 Overview
9.7.5.2 South & Central America Laronidase - Market Revenue and Forecast to 2028 (US$ Million)
9.7.6 Galsulfase (Naglazyme)
9.7.6.1 Overview
9.7.6.2 South & Central America Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.7 Hyaluronidase (Cumulase)
9.7.7.1 Overview
9.7.7.2 South & Central America Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)
9.7.8 Others
9.7.8.1 Overview
9.7.8.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)
9.8 Targeting Glycosphingolipids
9.8.1 Overview
9.8.2 South & Central America Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3 Imiglucerase (Cerezyme)
9.8.3.1 Overview
9.8.3.2 South & Central America Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.3 Agalsidase (Fabrazyme)
9.8.3.3.1 Overview
9.8.3.3.2 South & Central America Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.3.4 N-butyl-deoxynojirimycin (DNJ)
9.8.3.4.1 Overview
9.8.3.4.2 South & Central America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)
9.8.4 Others
9.8.4.1 Overview
9.8.4.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9 Others
9.9.1 Overview
9.9.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3 Acarbose
9.9.3.1 Overview
9.9.3.2 South & Central America Acarbose - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.3 Alglucosidase Alfa (Myozyme)
9.9.3.3.1 Overview
9.9.3.3.2 South & Central America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)
9.9.3.4 Allosamidin
9.9.3.4.1 Overview
9.9.3.4.2 South & Central America Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)
9.9.4 Others
9.9.4.1 Overview
9.9.4.2 South & Central America Others - Market Revenue and Forecast to 2028 (US$ Million)
10. South & Central America Glycomic Therapeutics Market Revenue and Forecast to 2028 - by Mode of Action
10.1 Overview
10.2 South & Central America Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)
10.2.1 South & Central America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
10.3 Inhibits Neuraminidase
10.3.1 Overview
10.3.2 South & Central America Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)
10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate
10.4.1 Overview
10.4.2 South & Central America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)
10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)
10.5.1 Overview
10.5.2 South & Central America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)
10.6 Tissue Plasminogen Activator
10.6.1 Overview
10.6.2 South & Central America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
10.7 Inhibits Glucosylceramide Synthase
10.7.1 Overview
10.7.2 South & Central America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
10.8 Interleukin 1 And 2 And 3
10.8.1 Overview
10.8.2 South & Central America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
10.9 Beta And Gamma Interferons
10.9.1 Overview
10.9.2 South & Central America Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)
10.10 Others
10.10.1 Overview
10.10.2 South & Central America Others- Market Revenue And Forecasts To 2028 (US$ Million)
11. South & Central America Glycomic Therapeutics Market Revenue and Forecasts to 2028 - Country Analysis
11.1 South & Central America: Glycomic Therapeutics Market
11.1.1 Overview
11.1.2 South & Central America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
11.1.2.1 Brazil: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.1 Brazil: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.1.2 Brazil: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.1.3 Brazil: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.1.3.1 Brazil: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.1.3.2 Brazil: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.1.3.3 Brazil: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.1.3.4 Brazil: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.1.4 Brazil: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.1.5 Brazil: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.2.2 Argentina: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.1 Argentina: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.2.2 Argentina: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.2.3 Argentina: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.2.3.1 Argentina: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.2.3.2 Argentina: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.2.3.3 Argentina: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.2.3.4 Argentina: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.2.4 Argentina: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.2.5 Argentina: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
11.1.2.3 Rest of South and Central America: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.1 Rest of SCAM: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
11.1.2.3.2 Rest of SCAM: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)
11.1.2.3.3 Rest of SCAM: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)
11.1.2.3.3.1 Rest of SCAM: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)
11.1.2.3.3.2 Rest of SCAM: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)
11.1.2.3.3.3 Rest of SCAM: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)
11.1.2.3.3.4 Rest of SCAM: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)
11.1.2.3.4 Rest of SCAM: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)
11.1.2.3.5 Rest of SCAM: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)
12. South & Central America Glycomic Therapeutics Market -Industry Landscape
12.1 Overview
12.2 Growth Strategies in the Glycomic Therapeutics Market (%)
12.3 Organic Developments
12.3.1 Overview
12.4 Inorganic Developments
12.4.1 Overview
13. Company Profiles
13.1 BioMarin Pharmaceutical Inc.
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Genzyme Corporation (Sanofi)
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Bayer AG
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 GlaxoSmithKline plc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 F. Hoffmann-La Roche Ltd
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Glycomic Therapeutics Market
LIST OF TABLES
Table 1. South & Central America: Glycomic Therapeutics Market Revenue and Forecasts to 2028, (US$ Million)
Table 2. South & Central America Glycomic Therapeutics Market, by C lass - Revenue and Forecast to 2028 (US$ Million)
Table 3. South & Central America Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (USD Million)
Table 4. South & Central America Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (USD Million)
Table 5. South & Central America Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (USD Million)
Table 6. South & Central America Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (USD Million)
Table 7. South & Central America Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (USD Million)
Table 8. South & Central America Glycomic Therapeutics Market, by Others- Revenue and Forecast to 2028 (USD Million)
Table 9. South & Central America Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (USD Million)
Table 10. Brazil Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 11. Brazil Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 12. Brazil Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 13. Brazil Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 14. Brazil Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 15. Brazil Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 16. Brazil Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 17. Brazil Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 18. Argentina Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 19. Argentina Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 20. Argentina Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 21. Argentina Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 22. Argentina Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 23. Argentina Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 24. Argentina Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 25. Argentina Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 26. Rest of SCAM Glycomic Therapeutics Market, by Class - Revenue and Forecast to 2028 (US$ Million)
Table 27. Rest of SCAM Glycomic Therapeutics Market, by Structure - Revenue and Forecast to 2028 (US$ Million)
Table 28. Rest of SCAM Glycomic Therapeutics Market, by Targeting Sialic Acid - Revenue and Forecast to 2028 (US$ Million)
Table 29. Rest of SCAM Glycomic Therapeutics Market, by Targeting Glycosaminoglycan - Revenue and Forecast to 2028 (US$ Million)
Table 30. Rest of SCAM Glycomic Therapeutics Market, by Targeting Glycosphingolipids - Revenue and Forecast to 2028 (US$ Million)
Table 31. Rest of SCAM Glycomic Therapeutics Market, by Others - Revenue and Forecast to 2028 (US$ Million)
Table 32. Rest of SCAM Glycomic Therapeutics Market, by Indication - Revenue and Forecast to 2028 (US$ Million)
Table 33. Rest of SCAM Glycomic Therapeutics Market, by Mode of Action - Revenue and Forecast to 2028 (US$ Million)
Table 34. Organic Developments in the Glycomic Therapeutics Market
Table 35. Inorganic Developments in the Glycomic Therapeutics Market
Table 36. Glossary of Terms in Glycomic Therapeutics Market
LIST OF FIGURES
Figure 1. South & Central America Glycomic Therapeutics Market Segmentation
Figure 2. South & Central America Glycomic Therapeutics Market, By Country
Figure 3. South & Central America Glycomic Therapeutics Market Overview
Figure 4. Synthetic Segment Held Largest Share of Class Segment in South & Central America Glycomic Therapeutics Market
Figure 5. Argentina is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. South & Central America: PEST Analysis
Figure 7. South & Central America Glycomic Therapeutics Market Impact Analysis of Driver and Restraints
Figure 8. South & Central America Glycomics market - Revenue Forecast and Analysis - 2020- 2028
Figure 9. South & Central America Glycomic Therapeutics Market, by Class 2022 & 2028 (%)
Figure 10. South & Central America Isolated Revenue and Forecasts to 2028 (US$ Million)
Figure 11. South & Central America Synthetic - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. South & Central America Glycomics Market, by Indication 2022 & 2028 (%)
Figure 13. South & Central America Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)
Figure 14. South & Central America Anaemia Revenue and Forecasts to 2028 (US$ Million)
Figure 15. South & Central America Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)
Figure 16. South & Central America Cataract Revenue and Forecasts to 2028 (US$ Million)
Figure 17. South & Central America Gaucher's diseases Revenue and Forecasts to 2028 (US$ Million)
Figure 18. South & Central America MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)
Figure 19. South & Central America Cancer Revenue and Forecasts to 2028 (US$ Million)
Figure 20. South & Central America Alzheimer's Revenue and Forecasts to 2028 (US$ Million)
Figure 21. South & Central America Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)
Figure 22. South & Central America Others Revenue and Forecasts to 2028 (US$ Million)
Figure 23. South & Central America Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)
Figure 24. South & Central America Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. South & Central America Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. South & Central America Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 27. South & Central America Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. South & Central America Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. South & Central America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. South & Central America Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 31. South & Central America Heparin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 32. South & Central America Hyaluronan (HA) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 33. South & Central America Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 34. South & Central America Guillain-Barre Syndrome - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 35. South & Central America Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 36. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 37. South & Central America Targeting Glycosphingolipids - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 38. South & Central America Imiglucerase (Cerezyme )- Market Revenue and Forecasts to 2028 (US$ Million)
Figure 39. South & Central America Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 40. South & Central America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 41. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 42. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 43. South & Central America Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 44. South & Central America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 45. South & Central America Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 46. South & Central America Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 47. South & Central America Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)
Figure 48. South & Central America Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 49. South & Central America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 50. South & Central America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 51. South & Central America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 52. South & Central America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 53. South & Central America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 54. South & Central America Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 55. South & Central America Others - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 56. South and Central America: Glycomic Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 57. South & Central America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)
Figure 58. Brazil: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 59. Argentina: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 60. Rest of SCAM: Glycomic Therapeutics Market - Revenue and Forecast to 2028 (US$ Million)
Figure 61. Growth Strategies in the Glycomic Therapeutics Market (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security